Genomictree Inc.

Equities

A228760

KR7228760005

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-23 EDT			5-day change	1st Jan Change
20,550 ^KRW	+1.23%		+1.99%	-0.24%

2023	Genomictree Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
2022	Tranche Update on Genomictree Inc.'s Equity Buyback Plan announced on May 17, 2022.	CI

Tranche Update on Genomictree Inc.'s Equity Buyback Plan announced on May 17, 2022.

August 18, 2022 at 03:09 am

From May 17, 2022 to June 30, 2022, the company has repurchased 211,270 shares, representing 1.04% for KRW 2,753.12 million. With this, the company has completed the repurchase of 211,270 shares, representing 1.04% for KRW 2,753.12 million under the buyback announced on May 17, 2022.

Latest news about Genomictree Inc.

Genomictree Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
Tranche Update on Genomictree Inc.'s Equity Buyback Plan announced on May 17, 2022.	22-11-18	CI
Tranche Update on Genomictree Inc.'s Equity Buyback Plan announced on May 17, 2022.	22-11-18	CI
Genomictree Inc.'s Equity Buyback announced on May 17, 2022, has expired with 380,360 shares, representing 1.86% for KRW 4,984.4 million.	22-11-15	CI
Tranche Update on Genomictree Inc.'s Equity Buyback Plan announced on May 17, 2022.	22-08-18	CI
Genomictree Inc. announces an Equity Buyback for KRW 5,000 million worth of its shares.	22-05-16	CI
Genomictree Inc. Ltd authorizes a Buyback Plan.	22-05-16	CI
Genomictree Inc. announced that it has received KRW 5.00000105 billion in funding from ORION Holdings Corp.	21-08-04	CI
Genomictree Inc. announced that it expects to receive KRW 5.00000105 billion in funding from ORION Holdings Corp.	21-07-27	CI
Genomictree Inc. agreed to acquire 4.8% stake in optoLANE Technologies Inc for KRW 5 billion.	21-05-26	CI
Genomictree Inc. announced that it has received KRW 59.9999768 billion in funding from a group of investors	21-04-29	CI
Genomictree Inc. announced that it expects to receive KRW 59.9999768 billion in funding from a group of investors	21-04-21	CI
Promis Diagnostics, Inc. announced that it has received $19.99999 million in funding from Genomictree Inc.	20-01-08	CI
Genomictree Inc.(KOSDAQ:A228760) added to S&P Global BMI Index	19-09-23	CI
Genomictree Inc. announced that it has received KRW 7 billion in funding	17-09-27	CI
Genomictree Inc. announced that it expects to receive KRW 7 billion in funding	17-09-25	CI

Chart Genomictree Inc.

Duration

Period

More charts

Company Profile

Genomictree Inc. is a Korea-based company mainly engaged in the genomic analysis. The Company is involved in conducting of genomic analysis using microarrays and next generation sequencing analysis. In addition, the Company is conducting clinical trials for molecular diagnostic products. Molecular diagnostic products include cancer molecular diagnostic products and molecular genetic diagnostic products. Cancer molecular diagnostic products include molecular diagnostic products for colorectal cancer, bladder cancer, lung cancer, stomach cancer, cervical cancer. Molecular genetic diagnostic products include epidermal growth factor receptor (EGFR) mutation diagnosis, as well as human papilloma virus (HPV) diagnostic products.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENOMICTREE INC.	-0.24%	361M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research